Skip to main content
      RT @Yuz6Yusof: #ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response i

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
      RT @bella_mehta: Abst#0001 MIRROR RCT at #ACR22 #plenary
      Pts with gout on #pegloticase and #gout
      sustained higher urat

      Bella Mehta bella_mehta

      3 years 10 months ago
      Abst#0001 MIRROR RCT at #ACR22 #plenary Pts with gout on #pegloticase and #gout sustained higher urate lowering response in pts cotreated with #MTX benefit beyond 6 months @rheumnow https://t.co/rTZ3fPaFJS
      RT @DrCassySims: Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow

      -Included patients with at least bilateral gra

      Catherine Sims, MD DrCassySims

      3 years 10 months ago
      Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow -Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI -5mg BID Xeljanz -Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo -Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt
      RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content c

      Dr. John Cush RheumNow

      3 years 10 months ago
      RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
      RT @Yuz6Yusof: #ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyeliti

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF
      RT @uptoTate: mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse model

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd
      RT @DrTrishHarkins: 🪞MIRROR RCT🪞

      💊MTX ⬆️ response of P

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
      RT @doctorRBC: Excellent start to the first plenary session!
      MIRROR study - MTX coadministration with pegloticase for go

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Excellent start to the first plenary session! MIRROR study - MTX coadministration with pegloticase for gout treatment - doubling of efficacy and 7x decrease in infusion reactions - less anti-PEG abs @RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
      RT @uptoTate: 2022 IIM-assoc'd CA screening key takeaways
      Most common CA: lung, ovarian, colorectal, lymphoma, breast, &

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      2022 IIM-assoc'd CA screening key takeaways Most common CA: lung, ovarian, colorectal, lymphoma, breast, & naso-pharyngeal High risk: DM, +anti-TIF1 gamma, +antiNXP2, >40 at IIM dx, severe/active dz, cutaneous necrosis, dysphagia Abs 0002 #ACR22 @RheumNow https://t.co/BhF1jJa8Oz https://t.co/oLVTLG34ck
      RT @drdavidliew: So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m

      David Liew drdavidliew

      3 years 10 months ago
      So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m
      RT @KDAO2011: Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir
      RT @synovialjoints: Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients ◦ Physical examination is meaningful and cannot be replaced by technology ◦ Don’t treat the EHR, treat the patient ◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw
      RT @drdavidliew: @MayoClinic data for bari in relapsing GCA caused waves at #ACR21

      Spanish data looking at real-world p

      David Liew drdavidliew

      3 years 10 months ago
      @MayoClinic data for bari in relapsing GCA caused waves at #ACR21 Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes waiting for SELECT-GCA with interest! @EBRheum ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3
      RT @ericdeinmd: Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
      BEL: lower risk of severe ifn (HR 0.81) and hospital

      Eric Dein ericdeinmd

      3 years 10 months ago
      Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr
      RT @DrTrishHarkins: ⬆️ correlation between BASDAI + ASQoL in 🙋‍♂️ vs 🙋‍♀️

      What does this mean?

      â

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      ⬆️ correlation between BASDAI + ASQoL in 🙋‍♂️ vs 🙋‍♀️ What does this mean? ❓low disease activity in 🙋‍♀️ resulting in more marked ⬇️ in QoL❓ OR ❓Is there a need for gender stratified tools of disease activity❓ Abst#0406 #ACR22 @RheumNow @Sineadm15
      ×